Login
Companies $XFOR
$2.84 +$0.01 (0.35%) After hours
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc

x4pharma.com

What Do They Do?

Licenses mavorixafor rights to pharmaceutical partners and sells XOLREMDI, an oral medicine for a rare immune disorder, through a specialty pharmacy.

How Do They Make Money?

Pharmaceutical partners pay an upfront license fee and may owe regulatory milestones and sales royalties; research services are paid for over time. The U.S. specialty pharmacy pays for product when it is delivered.

revenue
SegmentShareRevenue
License and other revenue
81%
Product revenue, net
Sold outright

19%

Who Are Their Customers?

In the U.S., a specialty pharmacy buys XOLREMDI and dispenses it to patients. International partners have rights to distribute and sell mavorixafor in their territories.

Do Revenues Turn Into Profits?

No. It lost $79.2M in FY2025.

Operating income, FY2025
−247% of revenue
▼ −139% (Loss) vs FY2024 (−$36.4M, −1400%)
Net income, FY2025
−226% of revenue
▼ −111% (Loss) vs FY2024 (−$37.5M, −1440%)
Free cash flow, FY2025
−244% of revenue
▲ +35% (Loss) vs FY2024 (−$131.2M, −5047%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +75%
vs $1.6M in Q3 FY2025
Net income
▲ +32% (Loss)
vs −$29.8M in Q3 FY2025
License and other revenue share of revenue recognized vs 11.3% in Q3 FY2025
Revenue over time
License and other revenue Product revenue, net
$50M$25M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support